The impact of COVID-19 on hypertension

prof. Reinhold Kreutz

Finerenone in CKD patients

prof. Michel Burnier

Progress in the treatment of heart failure with preserved ejection fraction

prof. Sverre Erik Kjeldsen

SGLT2 inhibitors and hypertension in CKD

prof. Bert-Jan H. van den Born

Small interfering RNA to treat hypertension

prof. A.H. Jan Danser

The ENABLE cost action on adherence

prof. dr hab. n. med. Przemysław Kardas

Measuring urine/plasma drug levels

dr Pankaj Gupta

Electronic monitoring of adherence in clinical trials

dr Bernard Vrijens

Effect of renal denervation beyond blood pressure

prof. Roland Schmieder

Ultrasound-mediated renal denervation: recent data

prof. Michel Azizi

Interventional therapies besides renal denervation: where do we stand?

dr Thomas Weber

Management of hypertension in OSA

prof. Gianfranco Parati, MD, FESC

Molecular aspects of OSA as the basis for TOD

prof. dr hab. n. med. Adrian Doroszko

New technologies to assess OSA out of the hospital

dr hab. n. med. Jacek Wolf, prezes PTNT

Epidemiology and physiology of hypertension in OSA

prof. Raphael Heinzer

LC-MS/MS in endocrine hypertension: From prospective studies to machine learning

prof. Graeme Eisenhofer

Artificial intelligence in radiology

dr hab. n. med. Maciej Piskunowicz

Interest of renal Doppler ultrasound

dr hab. n. med. Magdalena Maria Januszewicz

MRI markers of renal injury

dr Anna Caroli

Cardiac MRI in hypertension

dr hab. n. med. Mateusz Śpiewak

The place of vascular measurements

dr Rosa Maria Bruno

How to deal with blood pressure variability

prof. Grzegorz Bilo

New cuffless devices to measure blood pressure

prof. Grégoire Würzner

The place of home blood pressure monitoring

prof. George Stergiou